Showing results (201-210 of 283) with videos related to

Sort By:
Pageof 29
Gynecologic Oncology|November 12, 2021
Challenges in lower limb lymphoedema assessment based on limb volume change: Lessons learnt from the SENTIX prospective multicentre studyMartina Borčinová, Volker Ragosch, Jiří Jarkovský, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 6, 2018
The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology guidelines for the management of patients with cervical cancerDavid Cibula, Richard Pötter, François Planchamp, et al.
Virchows Archiv : an International Journal of Pathology|May 24, 2018
Correction to: The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients with Cervical CancerDavid Cibula, Richard Pötter, François Planchamp, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 25, 2018
The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients With Cervical CancerDavid Cibula, Richard Pötter, François Planchamp, et al.
Nature Communications|February 2, 2022
The WID-BC-index identifies women with primary poor prognostic breast cancer based on DNA methylation in cervical samplesJames E Barrett, Chiara Herzog, Allison Jones, et al.
International Journal of Cancer|August 6, 2019
Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancerIsabelle Ray-Coquard, David Cibula, Mansoor R Mirza, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 10, 2022
An Autologous Dendritic Cell Vaccine Promotes Anticancer Immunity in Patients with Ovarian Cancer with Low Mutational Burden and Cold TumorsJitka Fucikova, Michal Hensler, Lenka Kasikova, et al.
The Lancet. Oncology|March 17, 2022
Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trialRebecca Kristeleit, Alla Lisyanskaya, Alexander Fedenko, et al.
Gynecologic Oncology|July 23, 2021
Dendritic cell-based immunotherapy (DCVAC/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): A randomized, open-label, phase 2 trialDavid Cibula, Lukas Rob, Peter Mallmann, et al.
The Lancet. Oncology|April 12, 2021
Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 studyRobert L Coleman, Domenica Lorusso, Christine Gennigens, et al.
Pageof 29